Binzotim Eye Drops
Brinzolamide + Timolol eye prep
1 gm + 500 mg/100 ml
Eskayef Pharmaceuticals Ltd.
| Pack size | 5ml bot |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 550 AED |
Indications
Binzotim Eye Drops is used for:
Treatment of elevated IOP in, open-angle glaucoma, ocular HTN
Adult Dose
Ophthalmic
1 drop into the affected eye(s) twice daily.
Child Dose
Renal Dose
No studies have been conducted with Brinzolamide or with Timolol 5 mg/ml eye drops in patients with renal impairment. No dosage adjustment is necessary in patients with mild to moderate renal impairment.
Administration
For ocular use.
Patients should be instructed to shake the bottle well before use. After cap is removed, if tamper evident snap collar is loose, remove before using product.
To prevent contamination of the dropper tip and the suspension, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle. Instruct patients to keep the bottle tightly closed when not in use.
If more than one topical ophthalmic medicinal product is being used, the medicinal products must be administered at least 5 minutes apart. Eye ointments should be administered last.
Contra Indications
Bronchial asthma, severe COPD, sinus bradycardia, 2nd or 3rd degree AV block, overt cardiac failure, cardiogenic shock, severe allergic rhinitis, bronchial hyperreactivity, hyperchloraemic acidosis, severe renal impairment.
Precautions
Control cardiac failure prior to therapy. History of severe cardiac & resp disease. Patients subject to hypoglycemia or labile insulin-dependent diabetes. May mask hyperthyroidism or worsen Prinzmetal's angina, severe peripheral & central circulatory disorders & hypotension.
History of atopy or severe anaphylactic reaction to a variety of allergens. Avoid concomitant use of 2 local beta-adrenergic blockers or 2 local carbonic anhydrase inhibitors. Close monitoring of IOP in patients w/ pseudoexfoliative or pigmentary glaucoma. Narrow-angle glaucoma. Monitor patients w/ compromised corneas eg patients w/ DM or corneal dystrophies.
Remove contact lenses prior to application; reinsert after 15 min. May impair ability to drive or operate machinery. Pregnancy. Childn <18 yr.
Pregnancy-Lactation
Pregnancy
There are no adequate data regarding the use of ophthalmic brinzolamide and timolol in pregnant women. Studies in animals with brinzolamide have shown reproductive toxicity following systemic administration. Brinzolamide + Timolol should not be used during pregnancy unless clearly necessary.
Epidemiological studies have not revealed malformative effects but show a risk for intra uterine growth retardation when beta-blockers are administered by the oral route. In addition, signs and symptoms of beta-blockade (e.g. bradycardia, hypotension, respiratory distress and hypoglycaemia) have been observed in the neonate when beta-blockers have been administered until delivery. If Brinzolamide + Timolol is administered until delivery, the neonate should be carefully monitored during the first days of life.
Breast-feeding
It is not known whether ophthalmic brinzolamide is excreted in human breast milk. Studies in animals have shown that following oral administration brinzolamide is excreted in breast milk.
Beta-blockers are excreted in breast milk. However, at therapeutic doses of timolol in eye drops it is not likely that sufficient amounts would be present in breast milk to produce clinical symptoms of beta-blockade in the infant.
However, a risk to the suckling child cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Brinzolamide + Timolol therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Fertility
Studies have not been performed to evaluate the effect of topical ocular administration of Brinzolamide + Timolol on human fertility.
Non clinical data do not show any effects of either brinzolamide or timolol on male or female fertility following oral dosing. No effects on male or female fertility are anticipated from the use of Brinzolamide + Timolol.
Interactions
Brinzolamide: Concurrent use w/ oral carbonic anhydrase inhibitors may lead to additive systemic effects. Concurrent use w/ high-dose salicylates may lead to toxicity.
Timolol: Concomitant admin w/ reserpine may increase hypotension and bradycardia. Additive effects w/ other antihypertensives (e.g. hydralazine, methyldopa). Increased ?-adrenergic blockade (e.g. decreased heart rate) w/ quinidine. Rebound HTN due to abrupt withdrawal of clonidine. Hypotensive effect may be antagonised by NSAIDs (e.g. indomethacin, ibuprofen).
Adverse Effects
Side effects of Brinzolamide + Timolol eye prep :
Dysgeusia, blurred vision, eye pain & irritation, foreign body sensation.
Mechanism of Action
Brinzolamide is a carbonic anhydrase inhibitor that decreases secretion of aqueous humor thus reducing intraocular pressure.
Exact mechanism of ocular hypotensive effect is unclear, but it is thought to be related to reduction of aqueous humour formation. beta-blockade also causes lowering of BP.
Note
Binzotim 1 gm + 500 mg/100 ml Eye Drops manufactured by Eskayef Pharmaceuticals Ltd.. Its generic name is Brinzolamide + Timolol eye prep. Binzotim is availble in Bangladesh.
Farmaco BD drug index information on Binzotim Eye Drops is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.